Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized phase I/II platform study of novel ruxolitinib combinations in myelofibrosis
MOH_2021-12-08_010453Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib, siremadlin, rineterkib, crizanlizumab, sabatolimab and 1 more in myelofibrosis (MF) (6 arms), sponsored by Novartis. Primary endpoint: Response rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2021-12-08_010453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-08_010453.